Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 44, Issue 2, 2007, Pages 154-158

  Jespers, Vicky A ^a   Van Roey, Jens M ^b   Beets, Greet I ^b   Buvé, Anne M ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b Tibotec Pharmaceuticals Ltd   (Ireland)

Author keywords

Female controlled methods; HIV prevention; Microbicides; Phase 1 clinical trial; TMC120

Indexed keywords

DAPIVIRINE; PLACEBO;

ARTICLE; CERVICAL ERYTHEMA; CERVICAL PETECHIA; CLINICAL TRIAL; COLPOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CERVIX UTERI; COLPOSCOPY; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PURPURA; PYRIMIDINES; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 33847101873     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31802bb35f     Document Type: Article

References (40)

1. Joint United Nations Program on HIV/AIDS and World Health Organization. AIDS Epidemic Update. UNAIDS/05 19E. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS and World Health Organization; 2005.
2. Heise L, Elias C. Transforming AIDS prevention to meet women's needs: a focus on developing countries. Soc Sci Med. 1995;40:931-943.
3. Ramjee G. Microbicides and other prevention strategies. Presented at: XVI International AIDS Conference; 2006; Toronto. Available at: http://www.aids2006.org/PAG/PSession.aspx?s=653. Accessed September 5, 2006.
4. Stein Z. HIV prevention: the need for methods women can use. Am J Public Health. 1990;80:460-462.
5. Stone A. Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov. 2002;1:977-985.
6. Watts C, Vickerman P. The impact of microbicides on HIV and STD transmission: model projections. AIDS. 2001;15(Suppl):S43-S44.
7. Phase III trial updates. Presented at: Microbicides 2006, Cape Town, South Africa; 2006. Available at: http://www.microbicides2006.org/Feedback.htm. Accessed September 5, 2006.
8. Alliance for Microbicides. Microbicides clinical trials summary table. Available at: http://www.microbicide.org/publications/digest/ MicrobicideClinicalTrialsSummaryTable. September.pdf. 2006. Accessed September 5, 2006.
9. Scordi-Bello I, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother. 2005;49:3607-3615.
10. Shattock R, Solomon S. Microbicides - aids to safer sex. Lancet. 2004;363:1002-1003.
11. Parniak M. Nonnucleoside reverse transcriptase inhibitors as anti-HIV-1 microbicides. AIDS. 2001;15(Suppl):S56.
12. Van Herrewege Y, Vanham G, Michiels J, et al. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrob Agents Chemother. 2004;48:3684-3689.
13. de Bethune M, Andries K, Ludovici D, et al. TMC120 (R147681), a next generation NNRTI, has potent in vitro activity against NNRTI resistant HIV variants. Presented at: 8th Conference on Retroviruses and Opportunistic Infections (CROI) 2001; Chicago.
14. Jonckheere H, Azijn H, Roobaert F, et al. TMC120 and TMC125: NNRTIs active against resistant HIVas the result of a new and accelerated screening strategy. Presented at: 8th European Conference on Clinical Aspects and Treatment of HIV Infection, 2001; Athens.
15. Di Fabio S, Van Roey J, Giannini G, et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS. 2003;17:1597-1604.
16. Harman S, Watts P, Shattock R. TMC120 blocks HIV-1 infection in cellular and human cervical tissue models [abstract 02591]. Presented at: Microbicides 2004 Conference; 2004; London.
17. Van Herrewege Y, Michiels J, Van Roey J. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother. 2004;48:337-339.
18. CONRAD/WHO. Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products. Update. 2004; Geneva, Switzerland.
19. Nugent R, Krohn M, Hillier S. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29:297-301.
20. Mauck C, Baker J, Birnkrant D, et al. The use of colposcopy in assessing vaginal irritation in research. AIDS. 2000;14:2221-2227.
21. Mauck C, Weiner D, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception. 2001;64:383-391.
22. Mayer K, Maslankowski L, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543-551.
23. Schwartz J, Mauck C, Lai J, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception. 2006;74:133-140.
24. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 1998;12:433-437.
25. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect. 2000;76:126-130.
26. Keller M, Klotman M, Herold B. Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. J Antimicrob Chemother. 2003;51:1099-1102.
27. WHO/CONRAD. Technical consultation on nonoxynol-9. Reprod Health Matters. 2002;10:175-181.
28. Coggins C, Blanchard K, Alvarez F, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2000;76:480-483.
29. Vandebosch A, Goetghebeur E, Ramjee G, et al. Acceptability of COL-1492, a vaginal gel, among sex workers in one Asian and three African cities. Sex Transm Infect. 2004;80:241-243.
30. Ramjee G, Abdool Karim S, Morar N, et al. Acceptability of a vaginal microbicide among female sex workers. S Afr Med J. 1999;89:673-676.
31. Van't Klooster G, Gruzdev B, Horban A, et al. The novel non-nucleoside reverse transcriptase inhibitor TMC120 has potent antiretroviral activity after short-term monotherapy in treatment naive, HIV-1 infected subjects [abstract 9]. Presented at: 14th International Conference on Antiviral Research; 2001; Seattle. Antiviral Res. 2001;50:A40.
32. Borkow G, Barnard J, Nguyen TM, et al. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol. 1997;71:3023-3030.
33. Motakis D, Parniak M. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2002;46:1851-1856.
34. Fletcher P, Kiselyeva Y, Wallace G, et al. The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005;79:11179-11186.
35. Liu S, Lu H, Neurath A, et al. Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother. 2005;49:1830-1836.
36. Martinez J, Coplan P,Wainberg M. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res. 2006;71:343-350.
37. Van Damme L. Clinical microbicide research: an overview. Trop Med Int Health. 2004;9:1290-1296.
38. Wainberg M. Issues and implications for ARV-containing products. Presented at: Microbicides 2006, Cape Town, South Africa; 2006. Available at: http://www.microbicides2006.org/PDF/MarkWainberg.pdf.
39. Hu Q, Frank I, Williams V, et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med. 2004;199:1065-1075.
40. Masurier C, Salomon B, Guettari N, et al. Dendritic cells route human immunodeficiency virus to lymph nodes after vaginal or intravenous administration to mice. J Virol. 1998;72:7822-7829.